Ramiro Ribeiro - Mar 1, 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Medical Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/4/2024, 05:40 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Award $0 +125K $0.00 125K Mar 1, 2024 Common Stock 125K $28.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option to purchase will vest and become exercisable as follows: 25% at March 1st, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.